webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Mal-PEG5-NHS

  CAS No.: 1315355-92-0   Cat No.: BADC-00443   Purity: ≥98% 4.5  

Mal-PEG5-NHS is a biomedical product that assumes a pivotal role in drug conjugation and protein modification. Its exceptional reactivity as a linker fosters targeted drug delivery, thereby ramping up therapeutic efficacy to unprecedented levels.

Mal-PEG5-NHS

Structure of 1315355-92-0

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C24H35N3O12
Molecular Weight
557.55
Shipping
Room temperature, or blue ice upon request.

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
4,7,10,13,16-Pentaoxa-19-azadocosanoic acid, 22-(2,5-dihydro-2,5-dioxo-1Hpyrrol-1-yl)-20-oxo-, 2,5-dioxo-1-pyrrolidinyl ester;
IUPAC Name
(2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-[2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoate
Canonical SMILES
C1CC(=O)N(C1=O)OC(=O)CCOCCOCCOCCOCCOCCNC(=O)CCN2C(=O)C=CC2=O
InChI
InChI=1S/C24H35N3O12/c28-19(5-8-26-20(29)1-2-21(26)30)25-7-10-35-12-14-37-16-18-38-17-15-36-13-11-34-9-6-24(33)39-27-22(31)3-4-23(27)32/h1-2H,3-18H2,(H,25,28)
InChIKey
CBUSUMKXBREGEQ-UHFFFAOYSA-N
Appearance
Soild powder
Shipping
Room temperature, or blue ice upon request.

Mal-PEG5-NHS is a versatile bioconjugation reagent commonly used in the development of targeted therapies and diagnostic applications. It features a maleimide (Mal) group that allows for selective conjugation with thiol-containing molecules, such as peptides, proteins, or antibodies, and a polyethylene glycol (PEG5) spacer that enhances the solubility, stability, and bioavailability of the conjugate. The NHS (N-hydroxysuccinimide) ester is a reactive functional group that enables efficient coupling to amine groups, making this compound suitable for a wide range of applications in both therapeutic and research settings.

One of the key applications of Mal-PEG5-NHS is in the preparation of antibody-drug conjugates (ADCs) for targeted cancer therapy. The maleimide group allows the compound to conjugate to antibodies that specifically recognize tumor-associated antigens, while the PEG5 spacer improves the solubility and pharmacokinetics of the resulting conjugate. The NHS ester efficiently couples with amine-containing cytotoxic agents or small molecules, facilitating the attachment of potent drugs to the antibody. This targeted approach allows for the precise delivery of chemotherapy agents directly to the tumor, minimizing off-target effects and enhancing the therapeutic index of the treatment.

Mal-PEG5-NHS is also widely used in the design of other drug delivery systems, particularly for the development of peptide-drug conjugates or small molecule conjugates. The PEG5 spacer not only improves solubility and reduces immunogenicity but also ensures that the conjugate remains stable during circulation. The NHS ester is highly reactive with amine-containing drugs, facilitating the efficient attachment of therapeutic agents to the conjugate. This system allows for the controlled release of the drug at the disease site, making it ideal for precision medicine, where treatments can be directed specifically to target tissues such as tumors or infected cells.

In addition to drug delivery, Mal-PEG5-NHS is frequently used in diagnostic applications. It can be employed to conjugate diagnostic antibodies, peptides, or other biomolecules to imaging agents or sensors. The PEG5 spacer ensures that the conjugate maintains solubility and stability in biological environments, which is critical for maintaining effective tissue penetration and signal clarity in imaging studies. The NHS ester enables efficient conjugation to the amine-containing biomolecules, making Mal-PEG5-NHS an excellent choice for molecular imaging, biomarker detection, and diagnostics that require precise targeting of disease sites, such as cancerous tumors or inflammation.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: MMAE | BS2G Crosslinker (disodium) | UAA crosslinker 1 hydrochloride | MC-Ala-Ala-PAB | MC-AAA-NHCH2OCH2COOH | SuO-Glu-Val-Cit-PAB-MMAE | OH-Glu-Val-Cit-PAB-MMAE | NHS-PEG12-azide | Mal-PEG2-NHS ester | Azido-PEG2-NHS ester | Mal-PEG5-NHS
Send Inquiry
Verification code
Inquiry Basket